Clinical Trial

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-11; most recent amendment 2025-03-26.
Trial Details
NCT Number NCT05870163
Lead Sponsor Implantica CE Reflux Ltd.
Conditions Gastroesophageal Reflux Disease (GERD)
Enrollment 2,500 participants
Start Date 2023-02-20
Primary Completion 2025-12-01 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-01